Codi QR

Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma

Abstract Coronavirus disease 2019 (COVID‐19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID‐19 hyperimmune globulin (COVID‐HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP‐CorV (S...

Descripció completa

Guardat en:
Autors principals: Ding Yu, Yu‐Feng Li, Hong Liang, Jun‐Zheng Wu, Yong Hu, Yan Peng, Tao‐Jing Li, Ji‐Feng Hou, Wei‐Jin Huang, Li‐Dong Guan, Ren Han, Yan‐Tao Xing, Yong Zhang, Jia Liu, Lu Feng, Chun‐Yan Li, Xiao‐Long Liang, Ya‐Ling Ding, Zhi‐Jun Zhou, De‐Ming Ji, Fei‐Fei Wang, Jian‐Hong Yu, Kun Deng, Dong‐Mei Xia, De‐Mei Dong, Heng‐Rui Hu, Ya‐Jie Liu, Dao‐Xing Fu, Yan‐Lin He, Dong‐Bo Zhou, Hui‐Chuan Yang, Rui Jia, Chang‐Wen Ke, Tao Du, Yong Xie, Rong Zhou, Ce‐Sheng Li, Man‐Li Wang, Xiao‐Ming Yang
Format: Artigo
Idioma:Inglês
Publicat: Wiley 2022-05-01
Col·lecció:Advanced Science
Matèries:
COVID‐19 hyperimmune globulin
passive immunotherapy
SARS‐CoV‐2 variant
sinopharm COVID‐19 vaccine
Accés en línia:https://doi.org/10.1002/advs.202104333
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars